(Alliance News) - Shares in Indivior PLC plunged on Tuesday after it flagged lower than expected sales of its opioid treatment, Sublocade, and said it expects to take a charge relating to schizophrenia drug, Perseris.

In a wide-ranging trading update, the Richmond, Virginia-based specialty pharmaceuticals business, split off from Reckitt Benckiser PLC in 2014, said it would discontinue Perseris and announced the settlement of a litigation which was scheduled to proceed to trial next week.

The news sent shares in Indivior down by 42% to 688.10 pence each on Tuesday morning.

Indivior now expects 2024 net revenue between USD1.15 billion to USD1.22 billion, down from prior guidance of USD1.24 billion to USD1.33 billion.

Sales of Sublocade are seen between USD765 million to USD805 million, down from USD820 million from USD880 million.

Guidance for adjusted operating profit was lowered to between USD285 million to USD320 million from USD330 million from USD380 million before.

For the second quarter, net revenue is forecast between USD295 million to USD303 million, with Sublocade sales of USD188 million to USD196 million.

"Despite positive early performance trends at the start of the second quarter, Sublocade net revenue has continued to be impacted more than we expected by a combination of transitory factors, primarily the elimination of Covid emergency measures related to automatic Medicaid coverage renewals," Chief Executive Mark Crossley said.

At the end of the second quarter, Medicaid disenrollments stood at around 23 million versus around 19 million at the end of the first quarter.

In addition, Crossley noted the US government has extended renewal allowances for certain States which will further delay the annualisation of what he termed this "significant headwind".

Indivior said it had decided to discontinue sales and marketing for Perseris due to expected adverse impacts from increased payor management that crystalised in the second quarter.

This is expected to make the product no longer "financially viable", Indivior said.

"While we believe discontinuing Perseris is the right business decision, unfortunately it will impact our people and patients, and we will support them through this transition," Crossley said.

Indivior expects to take a USD65 million charge, of which around USD20 million is expected to be cash related to severance and termination of certain agreements. Around 130 jobs will be lost.

These charges will be taken in the second and third quarters, the company noted.

Ongoing annual operating expense savings are expected to be around USD50 million, with USD20 million expected to be realised in the second half.

Indivior also said it had, on Monday, settled a litigation with plaintiffs in the Health Care Services Corp.

Indivior has paid USD85 million to settle the case, which has been pending since 2020, which had been set to go to trial next week. Payment will be funded from Indivior's existing cash balance.

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights reserved.